Atlas Trials

Toripalimab in Combination With Chemotherapy and Antiangiogenic Agents in Patients With Non-Small Cell Lung Cancer After Failure of Immunotherapy (PD-1/L1 Inhibitors)

Clinical trial NCT05842018 · UNKNOWN

Trial details

NCT number
NCT05842018
Sponsor
Tianjin Medical University Cancer Institute and Hospital
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Non Small Cell Lung Cancer Recurrent
Start date
2023-05-01
Primary completion
2025-05-01
Enrollment
30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.